Irritable Bowel Syndrome Treatment Market Size, Share | 2031

Segments - Irritable Bowel Syndrome Treatment Market by Types (Constipation-predominant [Linzess/Constella, Amitiza, and Others], Diarrhea-predominant [Xifaxan, Viberzi, and Others]), Products (Xifaxan, Linzess/Constella, Viberzi, Amitiza, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023– 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Irritable Bowel Syndrome Treatment Market Outlook 2031

The Irritable Bowel Syndrome Treatment Market size was USD 2.50 Billion in 2022 and is likely to reach USD 5.47 Billion by 2031, expanding at a CAGR of 9.1% during 2023–2031. The growth of the market is attributed to the growing prevalence of target disease and rising uptake of drugs. In different regions commercialization of existing products is growing which drives the market.

Rising acceptance of Linzess in the U.S., Japan, and Europe is contributing in revenue growth. Irritable bowel syndrome (IBS) is most common gastrointestinal disorder affecting large intestine, with prevalence rate of around 10-12%, globally. Symptoms and signs include bloating, cramping, gas, constipation, abdominal pain, and diarrhea. Irritable bowel syndrome treatment includes change in diet, counselling, stress relief, and proper medicines.

Global Irritable Bowel Syndrome Treatment Market Outlook

The particular cause of symptoms is indefinite but it may disturb interaction between brain, nervous system, and gut. Due to this, changes occur in bowel sensation and movement. Based on survey conducted by the International Foundation for Gastrointestinal Disorders (IFFGD), around 2,050 IBS patients said that diagnosis of their conditions was completed 6.6 years after their symptoms initiated.

The market is neglected, with large number of opportunities for pharmaceutical companies to talk about numerous unmet needs in the therapy. Under clinical trials there are some promising products which increases the speed of the growth. Product sales are anticipated to raise considerably during the forecast period, majorly owing to growing prevalent population and commercialization of novel drugs for the treatment of constipation-predominant IBS.

Around 25-45% of patients take appointment of gastroenterologists because of symptoms of IBS. Still huge number of people are undiagnosed and unconscious about their symptoms which shows a medically known disorder. Because of this, various awareness campaigns are need to be organized to increase awareness about the condition. For instance, in April 2018, in the U.K., The IBS network conducted various activities to overcome the stigma about illness.

Irritable Bowel Syndrome Treatment Market Trends, Drivers, Restraints, and Opportunities

Growing geriatric population and increasing prevalence of gastrointestinal diseases are major factors responsible for the market growth in coming years.
Rising awareness about treatment and management of IBS among people and increasing inclination towards irritable bowel syndrome products are expected to fuel the market expansion during the forecast period.
Increasing prevalence of disorders including abdominal pain and bowel habit, unhealthy diet, and surge in level of stress is projected to drive the growth of the market.
Untapped potential present in emerging economies, sedentary lifestyle, and launched of several developed pipeline drugs for IBS treatment are anticipated to boost the market growth over the forecast period.
Lack of specific treatment which treat all symptoms of IBS is key factor that can hamper the market expansion during the forecast period.
Huge competition among major market players associated with pricing is projected to impede the market growth.

Scope of Irritable Bowel Syndrome Treatment Market Report

The report on the global irritable bowel syndrome treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Types (Constipation-predominant [Linzess/Constella, Amitiza, and Others], Diarrhea-predominant [Xifaxan, Viberzi, and Others]), Products (Xifaxan, Linzess/Constella, Viberzi, Amitiza, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., and Ardelyx

Irritable Bowel Syndrome Treatment Market Segment Insights

IBS-C segment is expected to grow at a rapid pace

Based on types, the irritable bowel syndrome treatment market is divided into constipation-predominant (IBS-C) and diarrhea-predominant (IBS-D). The IBS-C segment is subdivided into linzess/constella, amitiza, and others. Also, the IBS-D segment is subdivided into xifaxan, viberzi, and others. The IBS-C segment accounted for key share of the market due to growing prevalence of target diseases and increasing uptake of drugs including Linzess/Constella and Amitiza.

Moreover, the segment is anticipated to expand at a rapid pace during the forecast period owing to projected launch of products such as Tenapanor and SYN-010. These products are presently under clinical trials. Astellas Pharma, AstraZeneca, Ironwood Pharmaceuticals, Inc., and Allergan are some key players present in this segment.

Global Irritable Bowel Syndrome Treatment Market Type

Linzess/Constella segment is projected to hold a key market share

On the basis of products, the irritable bowel syndrome treatment market is segmented into xifaxan, linzess/constella, viberzi, amitiza, and others. The linzess/constella (linaclotide) segment is expected to hold a key share of the market during the forecast period owing to growing adoption of products in major regions including Japan, the U.S., Germany, UK, Italy, and Spain. In the U.S., Ironwood and Allergan marketed Linaclotide as a Linzess and in Europe Linaclotide is marketed as Constella by Allergan.

Global Irritable Bowel Syndrome Treatment Market Product

North America is expected to dominate the market

On the basis of regions, the irritable bowel syndrome treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is expected to exhibit a rapid growth rate in the coming years owing to existence of major market players, larger awareness among patients, huge presence of novel products, and well-established healthcare infrastructure.

On the other hand, the market of Europe is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing commercialization of IBS products, growing initiatives to increase awareness about disorder among people, and presence of a large target population.

Global Irritable Bowel Syndrome Treatment Market Region

Segments

The global irritable bowel syndrome treatment market has been segmented on the basis of

Types

Constipation-predominant (IBS-C)
- Linzess/Constella
- Amitiza
- Others
Diarrhea-predominant (IBS-D)
- Xifaxan
- Viberzi
- Others

Products

Xifaxan
Linzess/Constella
Viberzi
Amitiza
Others

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Ironwood Pharmaceuticals, Inc.
Allergan
Astellas Pharma, Inc.
Takeda Pharmaceutical Company Limited
AstraZeneca
Sebela Pharmaceuticals Inc.
Synergy Pharmaceuticals Inc.
Bausch Health,
Synthetic Biologics, Inc.
Ardelyx

Competitive Landscape

Key players competing in the irritable bowel syndrome treatment market are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., and Ardelyx.

Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in April 2015, Salix Pharmaceuticals was acquired by Bausch Health for expansion of its portfolio by focusing on gastrointestinal drugs. Also, in January 2019, AstraZeneca and Ironwood Pharmaceuticals got marketing approval of Linzess in China to make stronger position in the market.

Global Irritable Bowel Syndrome Treatment Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Irritable Bowel Syndrome Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Irritable Bowel Syndrome Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Irritable Bowel Syndrome Treatment Market - Supply Chain
  4.5. Global Irritable Bowel Syndrome Treatment Market Forecast
     4.5.1. Irritable Bowel Syndrome Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Irritable Bowel Syndrome Treatment Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Irritable Bowel Syndrome Treatment Market Absolute $ Opportunity
5. Global Irritable Bowel Syndrome Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
     5.3.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Irritable Bowel Syndrome Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
7. North America Irritable Bowel Syndrome Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
     7.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
8. Latin America Irritable Bowel Syndrome Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
     8.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
9. Europe Irritable Bowel Syndrome Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
     9.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Irritable Bowel Syndrome Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
     10.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Irritable Bowel Syndrome Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
     11.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Irritable Bowel Syndrome Treatment Market: Market Share Analysis
  12.2. Irritable Bowel Syndrome Treatment Distributors and Customers
  12.3. Irritable Bowel Syndrome Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Ironwood Pharmaceuticals, Inc.
     12.4.2. Allergan
     12.4.3. Astellas Pharma, Inc.
     12.4.4. Takeda Pharmaceutical Company Limited
     12.4.5. AstraZeneca
     12.4.6. Sebela Pharmaceuticals Inc.
     12.4.7. Synergy Pharmaceuticals Inc.